Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases.
Around the world, our medicines help millions of people in their fight against cancer, cardiovascular disease, diabetes, hepatitis B,
HIV/AIDS, rheumatoid arthritis and psychiatric disorders.
At Bristol-Myers Squibb, our BioPharma strategy uniquely combines the reach and resources of a major pharma company with the
entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers’ needs, giving maximum
priority to accelerating pipeline development, delivering sales growth and continuing to manage costs.
The strategy is working. For the past three years, our total return for shareholders, including dividends, has been among the best in the industry. We
outperformed most mega pharma companies, diversified companies and pure biotech companies. Reflecting our long-standing commitment to
deliver shareholder value, our company has paid dividends to stockholders for more than 300 consecutive quarters.
In addition, we have delivered nine new products to patients in the past seven years. And there are more medicines on
the way. We anticipate up to six additional regulatory approvals or submissions through 2012.
Our R&D organization is considered among the most productive in the industry. And the String of Pearls strategy of innovative alliances,
partnerships and acquisitions further enhances our internal capabilities. Our full array of 10 pearls encompasses many of our
key disease areas, including cancer, cardiovascular disease, immunology, neuroscience and virology.
Pursuing our Mission also means we are working to provide patient access to health care. We are striving to that goal through public/private partnerships
like SECURE THE FUTURE, our groundbreaking $150 million program to help confront HIV/AIDS in Africa. In addition, through our patient assistance programs, in 2009
we provided medicines worth more than $290 million at estimated wholesale list price to qualifying patients in the U.S.
Innovation is critical for successfully executing our BioPharma strategy. That innovation is enhanced by a diverse workforce and an inclusive culture.
Bristol-Myers Squibb has been recognized year after year as one of the best companies for female executives and working mothers. We’ve also been recognized by the
Human Rights Campaign Foundation’s Corporate Equality Index for achieving a perfect score for the past four consecutive years.
|